A major obstacle in the treatment of acute myeloid leukemia (AML) is refractory disease or
relapse after achieving remission. The latter arises from a few therapy-resistant cells within …

PURPOSE The combination of whole-genome and transcriptome sequencing (WGTS) is
expected to transform diagnosis and treatment for patients with cancer. WGTS is a …

The treatment landscape of acute myeloid leukemia (AML) is evolving, with promising
therapies entering clinical translation, yet patient responses remain heterogeneous, and …

Acute myeloid leukemia (AML) is one of the most common types of leukemia in adults. While
complete remission can be obtained with intensive chemotherapy in young and fit patients …

The current classification of acute myeloid leukemia (AML) relies largely on genomic
alterations. Robust identification of clinically and biologically relevant molecular subtypes …

Cytogenetics has long represented a critical component in the clinical evaluation of
hematologic malignancies. Chromosome banding studies provide a simultaneous snapshot …

Innovative multi-omics frameworks integrate diverse datasets from the same patients to
enhance our understanding of the molecular and clinical aspects of cancers. Advanced …

Targeted therapies have come to play an increasingly important role in cancer therapy over
the past two decades. This success has been made possible in large part by technological …

Drug resistance is a key factor in the treatment failure of acute myeloid leukemia (AML).
Nuclear factor E2-related factor 2 (Nrf2) plays a crucial role in tumor chemotherapy …

Acute myeloid leukemia (AML) with BCR:: ABL1 has recently been recognized as a distinct
subtype in international classifications. Distinguishing it from myeloid blast crisis chronic …